89bio Inc (ETNB)
8.97
-0.23
(-2.50%)
USD |
NASDAQ |
May 16, 16:00
8.96
-0.01
(-0.11%)
After-Hours: 20:00
89bio Cash from Operations (Quarterly): -39.72M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -39.72M |
December 31, 2023 | -34.29M |
September 30, 2023 | -30.36M |
June 30, 2023 | -34.45M |
March 31, 2023 | -30.08M |
December 31, 2022 | -27.10M |
September 30, 2022 | -14.82M |
June 30, 2022 | -14.84M |
March 31, 2022 | -24.34M |
December 31, 2021 | -28.24M |
September 30, 2021 | -13.45M |
Date | Value |
---|---|
June 30, 2021 | -20.11M |
March 31, 2021 | -14.98M |
December 31, 2020 | -14.03M |
September 30, 2020 | -12.94M |
June 30, 2020 | -11.52M |
March 31, 2020 | -7.752M |
December 31, 2019 | -11.13M |
September 30, 2019 | -6.197M |
June 30, 2019 | -3.964M |
March 31, 2019 | -4.167M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-39.72M
Minimum
Mar 2024
-3.964M
Maximum
Jun 2019
-19.72M
Average
-14.91M
Median
Cash from Operations (Quarterly) Benchmarks
Akero Therapeutics Inc | -35.14M |
Madrigal Pharmaceuticals Inc | -149.16M |
Viking Therapeutics Inc | -6.134M |
Galectin Therapeutics Inc | -4.702M |
Terns Pharmaceuticals Inc | -22.80M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | -79.90M |
Cash from Financing (Quarterly) | 21.03M |
Free Cash Flow | -138.82M |
Free Cash Flow Per Share (Quarterly) | -0.4144 |
Free Cash Flow Yield | -18.92% |